Prostate Cancer Prevention: Strategies and Realities

Prostate Cancer: Science and Clinical Practice

Volumn , Issue , 2003, Pages 89-99

  Uzzo, Robert G ^a   Kolenko, Vladimir ^a   Watkins Bruner, Deborah ^a   Engstrom, Paul F ^a   Horwitz, Eric M ^a   Konski, Andre ^a   Pollack, Alan ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2942589404     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012286981-5/50012-4     Document Type: Chapter

References (66)

1. J Noldus, M Graefen, A Haese, et al. (2000) Stage migration in clinically localized prostate cancer. Eur. Urol. 38 74
2. HB Carter, J Sauvageot, PC Walsh, et al. (1997) Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J. Urol. 157 2206
3. BF Hankey, EJ Feuer, LX Clegg, et al. (1999) Cancer surveillance series: interpreting trends in prostate cancer — part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J. Natl Cancer Inst. 1 1017
4. DP Byar (1990) The importance and nature of cancer prevention trials. Semin. Oncol. 17 413
5. DL Wickerham and E Tan-Chiu (2001) Breast cancer chemoprevention: current status and future directions. Semin. Oncol. 28 253
6. FR Khuri and SM Lippman (2000) Lung cancer chemoprevention. Semin. Surg. Oncol. 18 100
7. CA Coltman Jr, IM Thompson Jr and P Feigl (1999) Prostate Cancer Prevention Trial (PCPT) update. Eur. Urol. 35 544
8. IM Thompson Jr, M Kouril, EA Klein, et al. (2001) The Prostate Cancer Prevention Trial: current status and lessons learned. Urology 57 230
9. EA Klein, IM Thompson, SM Lippman, et al. (2001) Select: the next prostate cancer prevention trial. J. Urol. 166 1311
10. RT Greenlee, T Murray, S Bolden, et al. (2000) Cancer statistics, 2000. CA Cancer J. Clin. 50 7
11. DS Coffey (2001) Similarities of prostate and breast cancer: evolution, diet, and estrogens. Urology 57 31
12. FF Angwafo (1998) Migration and prostate cancer: an international perspective. J. Natl Med. Assoc. 90 S720
13. RM Benoit and MJ Naslund (1995) Detection of latent prostate cancer from routine screening: comparison with breast cancer screening. Urology 46 533
14. RG Uzzo, D Herzlinger and ED Vaughan Jr (1996) Prostate development: hormonal and cellular considerations. American Urologic Association Update Series 15 1
15. E Shapiro (1990) Embryonic development of the prostate. Insights into the etiology and treatment of benign prostatic hypertrophy. Urol. Clin. North Am. 17 487
16. GR Cunha (1994) Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer 74 1030
17. DS Coffey, SJ Berry and LL Ewing (1987) An Overview of Current Concepts in the Study of Benign Prostatic Hyperplasia. Washington, DC: United States General Printing Office 1-14
18. JE McNeal (1978) Origin and evolution of benign prostatic enlargement. Invest. Urol. 15 340
19. GR Cunha, ET Alarid, T Turner, et al. (1992) Normal and abnormal development of the male urogenital tract Role of androgens, mesenchymal-epithelial interactions, and growth factors. J. Androl. 13 465
20. LM Franks (1973) Proceedings: Etiology, epidemiology, and pathology of prostatic cancer. Cancer 32 1092
21. JM Kozlowski and JT Grayhack (1996) Carcinoma of the Prostate. 3rd edn Philadelphia: Mosby 1575-1713
22. T Shiraishi, M Watanabe, H Matsuura, et al. (1994) The frequency of latent prostatic carcinoma in young males: the Japanese experience. In Vivo 8 445
23. WJ Catalona (1984) Prostate Cancer. New York: Grune and Stratton, Inc
24. KJ Pienta (1998) Etiology, epidemiology, and prevention of carcinoma of the prostate. PC Walsh, AB Retik, ED Vaughan, et al., (Eds) 7th edn Campoell's Urology Vol. 3 Philadelphia: W.B. Saunders 2489-2496
25. EA Plantz, PW Kantoff and E Giovannucci (2000) Epidemiology of risk factors for prostate cancer. EA Klein,(Eds) Management of Prostate Cancer Totowa: Humana Press 19-45
26. WG Nelson, AM De Marzo and TL DeWeese (2001) The molecular pathogenesis of prostate cancer: implications for prostate cancer prevention. Urology 57 39
27. JM Cunningham, A Shan, MJ Wick, et al. (1996) Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res. 56 4475
28. T Visakorpi, AH Kallioniemi, AC Syvanen, et al. (1995) Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res. 55 342
29. JA Macoska, TM Trybus, WA Sakr, et al. (1994) Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. Cancer Res. 54 3824
30. GJ Kelloff, R Lieberman, VE Steele, et al. (2001) Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology 57 46
31. GJ Kelloff, ET Hawk, JA Crowell, et al. (1996) Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology 10 1471
32. FS Collins (1999) The human genome project and the future of medicine. Ann. N. Y. Acad. Sci. 882 42
33. B Kuska (1996) Cancer genome anatomy project set for takeoff. J. Natl Cancer Inst. 88 1801
34. WG Nelson and G Wilding (2001) Prostate cancer prevention agent development: criteria and pipeline for candidate chemoprevention agents. Urology 57 56
35. R Lieberman, WG Nelson, WA Sakr, et al. (2001) Executive summary of the National Cancer Institute Workshop: highlights and recommendations. Urology 57 4
36. DG Bostwick and J Qian (2001) Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia. Urology 58 91
37. H Wiseman (2000) The therapeutic potential of phytoestrogens. Expert Opin. Invest. Drugs 9 1829
38. P Ekman, H Gronberg, H Matsuyama, et al. (1999) Links between genetic and environmental factors and prostate cancer risk. Prostate 39 262
39. LC Clark, GFJ Combs, BW Turnbull, et al. (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276 1957
40. MA Moyad, SK Brumfield, KJ Pienta and E Vitamin (1999) alpha- and gamma-tocopherol, and prostate cancer. Semin. Urol. Oncol. 17 85
41. PH Gann, J Ma, E Giovannucci, et al. (1999) Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res. 59 1225
42. OP Heinonen, D Albanes, J Virtamo, et al. (1998) Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J. Natl Cancer Inst. 90 440
43. H Wei (1992) Activation of oncogenes and or inactivation of anti-oncogenes by reactive oxygen species. Med. Hypatheses 39 267
44. P Hainaut and J Miller (1993) Redox modulation of p53 conformation and sequence-specific DNA binding. Cancer Res. 53 4469
45. EA Klein and FL Meyskens Jr (2001) Potential target populations and clinical models for testing chemopreventive agents. Urology 57 171
46. F Algaba, JI Epstein, G Fabus, et al. (1995) Working standards in prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Pathol. Res. Pract. 191 836
47. O Cussenot, A Valeri, P Berthon, et al. (1998) Hereditary prostate cancer and other genetic predispositions to prostate cancer. Urol. Int. 60 30
48. MR Cupp and JE Oesterling (1993) Prostate-specific antigen, digital rectal examination, and transrectal ultrasonography: their roles in diagnosing early prostate cancer. Mayo Clin. Proc. 68 297
49. DW Bruner, A Baffoe-Bonnie, S Miller, et al. (1999) Prostate cancer risk assessment program. A model for the early detection of prostate cancer. Oncology (Huntingt) 13 325
50. WJ Catalona, JP Richie, FR Ahmann, et al. (1994) Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol. 151 1283
51. C Mettlin, G Jones, H Averette, et al. (1993) Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J. Clin. 43 42
52. GE Smith, MJ DeHaven, JP Grundig, et al. (1997) African-American males and prostate cancer: assessing knowledge levels in the community. J. Natl Med. Assoc. 89 387
53. SC Grumet, J James, DW Bruner, et al. (1999) Risk perceptions and attitudes regarding genetic testing in men at risk for prostate cancer. J. Gen. Counseling 8 378
54. A Rokman, T Ikonen, N Mononen, et al. (2001) ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer Res. 61 6038
55. L Wang, SK McDonnell, DA Elkins, et al. (2001) Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res. 61 6494
56. TR Rebbeck, JM Jaffe, AH Walker, et al. (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst. 90 1225
57. AH Walker, JM Jaffe, S Gunasegaram, et al. (1998) Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Human Mutat. 12 289
58. JM Jaffe, SB Malkowicz, AH Walker, et al. (2000) Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res. 60 1626
59. RK Nam, A Toi, D Vesprini, et al. (2001) V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology 57 199
60. JM Chan, MJ Starnpfer, E Giovannucci, et al. (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 563
61. O Cussenot and A Valeri (2001) Heterogeneity in genetic susceptibility to prostate cancer. Eur. J. Intern. Med. 12 11
62. JV Tricoli, DL Winter, AL Hanlon, et al. (1999) Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer. Urology 54 178
63. JS Schwartz, CE Lewis, C Clancy, et al. (1991) Internists' practices in health promotion and disease prevention. Ann. Intern. Med. 114 46
64. CM Valente, J Sobal, HL Muncie, et al. (1986) Health promotion: physicians' beliefs, attitudes, and practices. Am. J. Prev. Med. 2 82
65. JR Beck, MW Kattan and BJ Miles (1994) A critique of the decision analysis for clinically localized prostate cancer. J. Urol. 152 1894
66. R Lieberman (2001) Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development. Urology 58 83